TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to provide a customer update on its newly acquired subsidiary, Intrahealth Systems Limited (“Intrahealth”), highlighting the successful new implementation of Intrahealth’s Profile (“Profile”) Electronic Health Records (“EHR”) with Toronto Public Health (“TPH”), a health unit responsible for delivering public health programs and services, enforcing public health regulations and reporting to the Toronto Board of Health on public health issues. Intrahealth is in the final stages of its EHR implementation with TPH, which is expected to go live within the next few weeks.
Dorian Prior, President of Intrahealth commented, “We are thrilled with the continued success of Intrahealth in establishing ourselves as a premier EHR platform across Canada. Overall, Intrahealth has been strengthening its presence in the Ontario Public Health space with the most EHR systems deployed in public health units across Ontario. The TPH installation comes on the back of implementing systems at two additional public health authorities in Ontario over the past year. We firmly believe that working closely with public health organizations and government bodies is not only a testament to our current success but also a key part of our future strategy in driving widespread adoption of Intrahealth’s platform, especially as we start to roll out our AI powered product enhancements.”
Dr. Alexander Dobranowski, CEO of HEALWELL added, “We are pleased to announce another customer win for our Intrahealth platform, strengthening our presence in the Province of Ontario even further. We are grateful and excited to be working with Toronto Public Health to help protect and promote the health of millions of Toronto residents and look forward to adding more value to this relationship as we roll out platform updates which include AI powered tools and functionality.”
Intrahealth was awarded the TPH contract through a competitive RFP bidding process. Intrahealth has an active pipeline of new contract opportunities, including recently responding to servicing markets such as mental health, home health and multidisciplinary specialists, which the Company expects will be announced in the coming months. Profile offers a flexible environment that allows public health units the ability to customize the platform to meet the various needs of the diverse programs they manage. In addition to the ability to tailor the provider experience, so that providers have the right information at the right time, Profile also enables public health units to manage patient privacy across a large organization.
TPH is a dynamic and integral component of Toronto's health sector, reporting directly to the Board of Health with a vital mandate: safeguarding and enhancing the health and well-being of over three million residents. Since 1883, TPH has been at the forefront of public health initiatives, tirelessly working to prevent the spread of diseases, promote healthy living, and advocate for conditions that uplift the overall health of Toronto's diverse population. Utilizing cutting-edge surveillance methods, TPH monitors the health status of communities, allowing for proactive responses to both ongoing and emerging health needs. Through the development and implementation of public policies and practices, TPH strives to enhance the health of individuals, communities, and the entire city, solidifying its role as a cornerstone in Toronto's public health landscape.
Since its acquisition by HEALWELL earlier this year, Intrahealth has been working on leveraging HEALWELL’s AI technology and product capabilities and planning new functionality such as AI powered medical co-pilot capabilities. Such product enhancements can be quite impactful in terms of helping care providers improve operational efficiency.
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
About Intrahealth
Intrahealth is a pioneering force in healthcare technology, specializing in the development and implementation of state-of-the-art EMR or HER solutions. With a relentless commitment to advancing patient care, Intrahealth empowers healthcare providers, institutions, and governments with innovative digital tools designed to enhance healthcare delivery and improve patient outcomes. For more information about the Intrahealth, please visit our official website. https://intrahealth.com/
Forward Looking Statements
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including its expected revenue and ability to finalize service agreements with new customers, and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "to become", "improve", "growth", "ensuring", "continue", "anticipated", "expects", "proceed", "potential", "future", "consider", "result in", "increase", "deliver", "emerging", “is poised”, "plan", "position", "opportunities", "expansion", "exercise", "ensure", "achieve", "acquire", "complete", "satisfy", "entitle", "subject to" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the stability of general economic and market conditions; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2023, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$2.10 |
Daily Change: | -0.09 -4.11 |
Daily Volume: | 1,938,211 |
Market Cap: | C$348.350M |
December 03, 2024 November 12, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB